BeiGene’s Brukinsa quickly passes HIRA’s reimbursement review

Korea Biomedical Review

7 April 2022 - BeiGene’s Brukinsa (zanubrutinib), a next-generation BTK inhibitor, passed the Health Insurance Review and Assessment Service’s Cancer Drugs Benefit Appraisal Committee review just 40 days after winning marketing approval in Korea.

Merck’s anti-PD-L1 immunotherapy Bavencio (avelumab) and AstraZeneca’s PARP inhibitor Lynparza (olaparib) will expand bladder and prostate cancer indications.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder